

1

Title Page

2 **Full title:** COVID-19 with early neurological and cardiac thromboembolic phenomena—
3 timeline of incidence and clinical features.

4

5 **Authors:**

6 1. Dr Uma Sundar¹, MD.

7 2. Dr Sanah Merchant², MD.

8 3. Dr Meera Shah², MD.

9 4. Dr Amita Mukhopadhyay³, MD.

10 5. Dr Shaonak Kolte⁴, MBBS.

11 6. Dr Pramod Darole⁵, MD.

12 7. Dr Sharvari Mahajan⁶, MBBS.

13 8. Dr Ashank Bansal⁷, MD.

14 9. Dr Satish Gosavi⁸, MD.

15 10. Dr Dnaneshwar Asole⁹, DNB (Neurology).

16 11. Dr Niteen D Karnik¹, MD.

17 12. Dr Ajay Mahajan¹⁰, DM (Cardiology).

18 13. Dr Anagha Joshi¹¹, MD.

19

20 **Author Affiliations** (as per superscripted numbers above):

21 1. Professor, Medicine. Lokmanya Tilak Municipal Medical College and General

22 Hospital (LTMMC&GH), Sion, Mumbai 400022, Maharashtra, India.

23 2. Assistant Professor, Medicine. LTMMC&GH, Mumbai, India.

- 24 3. Associate Professor, Community Medicine. Dr Chandramma Dayananda Sagar
25 Institute of Medical Education and Research, Kanakapura 562112, Ramanagara
26 District, Karnataka, India.
- 27 4. Research assistant, Medicine. LTMMC&GH, Mumbai, India.
- 28 5. Associate Professor, Medicine. LTMMC&GH, Mumbai, India.
- 29 6. Research assistant, Cardiology. LTMMC&GH, Mumbai, India.
- 30 7. Assistant Professor, Radiology. LTMMC&GH, Mumbai, India.
- 31 8. Senior resident, Medicine. LTMMC&GH, Mumbai, India.
- 32 9. Assistant Professor, Neurology. LTMMC&GH, Mumbai, India.
- 33 10. Professor, Cardiology. LTMMC&GH, Mumbai, India
- 34 11. Professor, Radiology. LTMMC&GH, Mumbai, India.

35 Corresponding Author: Dr Amita Mukhopadhyay

36 Email: dr.amukho@gmail.com

37

38 Total number of tables and figures: Tables 3; Figures 1.

39 Word Count: Abstract 299; Text 3125.

40

41

42

43

44

45

46

47

48

49

Abstract

50 **Background:** At our tertiary care public hospital, we saw COVID-19 presenting with
51 thromboembolic phenomena, indicating a possible early thrombo-inflammatory pathology.

52 **Objectives:** We documented patients with cardiac and neurological thromboembolic
53 phenomena as a primary presentation of COVID-19, and compared a subset of COVID
54 associated strokes against COVID-19 patients without thrombotic manifestations.

55 **Methods:** We included all COVID-Stroke and COVID-ACS (COVID-19, with ischemic
56 arterial stroke/Acute Coronary Syndrome presenting prior to/simultaneous with/within 72
57 hours of systemic/respiratory COVID manifestations) admitted from April to
58 November 2020. In the nested case control analysis, we used unpaired T-test and chi-square
59 test to study differences between COVID-Stroke (case group) and non-thrombotic COVID
60 controls.

61 **Results and Conclusions:** We noted 68 strokes and 122 ACS associated with COVID-
62 19. ACS peaked in May-June, while stroke admissions peaked later in September-October,
63 possibly because severe strokes may have expired at home during the lockdown.
64 In the case-control analysis, cases (n=43; 12F:31M; mean age 51.5 years) had significantly
65 higher D-Dimer values than controls (n=50; 9F:41M; mean age 51.6 years). Mortality was
66 significantly higher in cases (51.2% vs. 26.0%; $p = 0.018$). We noted 7.5 times higher
67 mortality in cases versus controls even among patients needing minimal oxygen
68 support. Imaging in 37 patients showed both anterior and posterior circulation territories
69 affected in seven, with almost half of Carotid territory strokes being large hemispherical
70 strokes. Additionally, CT/MRI angiography in 28 strokes showed large vessel occlusions in
71 19 patients. Death in cases thus probably occurred before progression to intense respiratory
72 support, due to severe central nervous system insult.

73 Binary logistic regression analysis showed respiratory support intensity to be the sole
74 independent predictor of mortality among cases. Respiratory distress could have been due to
75 COVID-19 lung infection or aspiration pneumonia resulting from obtunded sensorium. In
76 controls, mortality was predicted by increasing age, female sex, and respiratory
77 support intensity.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95 **COVID-19 with early neurological and cardiac thromboembolic phenomena—timeline**
96 **of incidence and clinical features**

97 **Introduction**

98 COVID-19 is caused by the SARS-CoV-2 virus, a member of the Coronaviridae family.

99 There are numerous reports of patients with COVID-19 presenting with both arterial (stroke,
100 myocardial infarction) and venous thrombosis (deep vein thrombosis, pulmonary
101 thromboembolism, cerebral venous sinus thrombosis).(1–10) Accelerated thrombogenesis in
102 COVID-19 is postulated to be due to Virchow’s triad, resulting in endothelial dysfunction,
103 abnormal flow and a hypercoagulable state.(11–13) At our tertiary care public hospital, we
104 saw COVID-19 presenting with thromboembolic phenomena, where the respiratory
105 involvement was either very mild and simultaneous, or occurred only later during
106 hospitalization, indicating a possible early thrombo-inflammatory pathology, in a subsection
107 of patients. Hence, we documented patients with cardiac and neurological thromboembolic
108 phenomena as a primary presentation of COVID-19. Further, we compared clinical and
109 inflammatory markers in a subset of these patients with markers in patients without
110 thrombotic manifestations of the disease during hospitalization.

111 **Aims**

112 We aimed to document the incidence of acute thromboembolism, namely, ischemic stroke
113 and acute coronary syndrome (ACS) as a presentation of COVID-19. We also aimed to
114 compare clinical and inflammatory markers in a subgroup of patients of COVID-19 with
115 acute ischemic stroke at presentation or within the first 72 hours of other signs and symptoms
116 of COVID-19, with the parameters in patients presenting with respiratory onset disease. This
117 latter group had neither cardiac nor neurological ischemic pathology during their
118 hospitalization.

119 **Methodology**

120 Our study center is a 1400 bedded, tertiary care, municipal public hospital in Mumbai, India.
121 We did a retrospective observational serial recruitment of all cases satisfying the inclusion
122 criteria, followed by a nested case control analysis of a subset of the larger cohort of COVID-
123 19 patients.

124 ***Operational definitions:***

125 **Ischemic stroke:** Patients who presented to the hospital with ischemic arterial stroke, without
126 systemic or respiratory signs and symptoms of COVID-19 at admission, or stroke developing
127 within 72 hours of systemic or respiratory signs and symptoms of COVID-19, were included
128 from a study period of April to November 2020. Any of the symptoms comprising fever,
129 myalgia, throat pain, dry cough, tachypnoea, loose motions, and an oxygen saturation under
130 95% on room air at admission were considered as indicative of presence of systemic and
131 respiratory signs of COVID-19.

132 **Acute coronary syndrome:** Patients who presented to the hospital with ACS {ST segment
133 elevation myocardial infarction (STEMI) or Non-ST segment elevation myocardial infarction
134 (NSTEMI), or Unstable angina, diagnosed as per standard criteria} without systemic or
135 respiratory signs and symptoms of COVID-19 at admission, or ACS developing within 72
136 hours of systemic or respiratory signs and symptoms of COVID-19, were included in a
137 similar manner.

138 Patients with pulmonary or other systemic and peripheral thromboembolism and patients with
139 cerebral venous sinus thrombosis (CVST) were not included in the detailed analysis in this
140 study, unless associated with stroke or ACS, as a separate registry is being maintained for
141 them.

142 ***Inclusion in case group and control group:***

143 We compared clinical and inflammatory markers inpatients of COVID-19 with
144 thromboembolic phenomena (acute ischemic stroke) at presentation or within the first 72
145 hours of other signs and symptoms of COVID-19, with the parameters in patients presenting
146 with respiratory onset disease. The latter group continued to be free of cardiac and
147 neurological ischemic pathology till discharge. We selected the group with acute ischemic
148 stroke as the case group, as complete data was available for the patients with COVID-19
149 associated stroke. Thus, we analyzed detailed data for 43 COVID-19 cases with associated
150 stroke, and 50 controls with COVID-19 and no associated thromboembolic events.

151 Controls were included in a number similar to the cases. The selection of controls from any
152 given month of the study duration (April to November 2020), corresponded to the proportion
153 of COVID strokes to total COVID-19 cases, for that month. As strokes were highest in
154 proportion to total COVID-19 cases in September and October 2020, the maximum number
155 of controls were taken from that period. Selection of individual cases was by using random
156 computer-generated numbers.

157 We evaluated and compared demographic features (age, gender), clinical features
158 (comorbidities, oxygen saturation at admission and modality of maximum oxygen support
159 required during hospitalization), laboratory parameters {inflammatory markers such as C
160 Reactive Protein (CRP) and D-Dimer, creatinine level, platelet count}, mortality and
161 predictors of mortality in the case group versus the control group. Modalities of respiratory
162 support included, in order of increasing intensity, nasal cannula, venturi mask, non-
163 rebreathing bag and mask (NRBM), high flow nasal cannula (HFNC), non-invasive
164 ventilation (NIV), and intubation and mechanical ventilation. In the correlation of in-hospital
165 mortality with requirement for respiratory support, we divided the patients into two groups.
166 The low flow oxygen support subgroup included patients on room air, nasal cannula and

167 venturi mask, and the high flow oxygen support subgroup included patients on NRBM,
168 HFNC, NIV and intubation with mechanical ventilation.

169 We used Microsoft Excel (2010) to tabulate and clean the raw data, and to generate pivot
170 tables and graphs. We imported the excel datasheet into IBM SPSS version 20.0 and
171 performed univariate and multivariate analyses. We divided the study set into subgroups
172 according to relevant characteristics, and used the unpaired samples T-test and chi-square test
173 to study differences in key variables. We assumed unequal variances in reporting T tests. We
174 calculated 95% confidence intervals for mean differences and odds ratios, and considered a p
175 value below 0.05 to be statistically significant only if the confidence intervals for the
176 concerned statistic were congruent. We performed binary logistic regression to determine the
177 key predictors of in-hospital mortality. We entered the following variables as independent
178 predictors for both case and control groups: age, sex, number of comorbidities and respiratory
179 distress level (the last coded on an ascending scale reflecting the intensity of mode of
180 supplementary oxygen delivery, where 0 represented no support required, and 6 represented
181 invasive ventilation). CRP and D-Dimer were not added as predictors to this model, as
182 laboratory reports for both markers were available for only 20 cases. In the initial days of the
183 pandemic, logistic pressures on the hospital made it difficult to procure reports for all
184 patients.

185 *Ethical considerations:* We obtained scientific and ethical approval for the study from the
186 Human Research Institutional Ethics Committee, Lokmanya Tilak Municipal Medical
187 College and General Hospital, Sion, Mumbai.

188 *Data availability statement:* The data used in our analysis will be made available to
189 researchers upon reasonable request to the corresponding author.

190 **Results**

191 Figure 1 shows that during the period of April-November 2020, there were 4,069 COVID-19
192 cases admitted in our hospital. There were 68 cases of stroke associated with COVID-19 and
193 122 cases of ACS associated with COVID-19. The peak of total COVID-19 cases and cardiac
194 cases was in May and June 2020. The peak of stroke cases was in September and October
195 2020. Among the 68 patients with stroke, 49 had ischemic stroke. Of these 49 patients, 43
196 satisfied inclusion criteria for early presentation as ischemic stroke as per our operational
197 definitions. The case records of these 43 patients (case group) were analyzed in detail. Close
198 to half of the 43 patients in the case group (21; 48.9%) belonged to the 41-60 years age
199 group. Among them, 11 were aged 51-60 years, and 10 were 41-50 years of age. Whereas out
200 of 50 controls, 13 patients (26.0%) were aged 61-70 years, followed by 11 each (22.0%) in
201 the 31-40 years and 51-60 years age groups, respectively.

202 The sex distribution of cases and controls was as follows: 12 (27.9%) women and 31 (72.1%)
203 men in the case group, versus 9 (18.0%) women and 41 (82.0%) men in the control group.

204 There was no significant difference in the age or sex distribution of case and control groups.

205 Among the cases, 14 of 43 patients (32.6%) were free of comorbidities, compared to 22 of 50
206 controls (44.0%). Among the cases there were 9 patients with hypertension (HTN), 4 with
207 diabetes mellitus (DM), and 12 who had both comorbidities. Among the controls, 6 patients
208 had HTN, 11 had DM, and 9 had both. These differences were not statistically significant.

209 Among the 43 stroke cases, we noted 40 patients with pure arterial infarcts, one with arterial
210 infarct associated with CVST, and two patients with bithalamic infarcts, possibly due to
211 blockage of artery of Percheron or vein of Galen. As CT angiography and venography were
212 not available for these two patients, they were classified as of indeterminate (arterial/venous)
213 etiology. CT scans pinpointed the vascular territory affected in 37 of 41 patients (40 pure
214 arterial infarcts and one infarct+CVST) with arterial infarcts. Of these, 26 (70.3% of 37) had

215 infarcts in the carotid territory, four (10.8% of 37) in the vertebrobasilar territory, and seven
216 patients (18.9% of 37) had infarcts in both territories. Additionally, four patients were
217 clinically diagnosed as carotid territory infarct, although their initial CT scans revealed no
218 acute changes (repeat CTs were not done either due to logistic constraints or clinical
219 deterioration). Among the 33 carotid ischemic strokes with CT scans available (comprising
220 carotid territory strokes and carotid component of mixed territory strokes), 15 were classified
221 as large hemispherical, 10 were subcortical and 8 were pure cortical infarcts.

222 Among the 43 stroke patients, 28 (65.1%) had a CT angiography or MRI angiography done.
223 Large vessel occlusion (LVO) was present in 19/28 (67.8%) patients.

224 As seen in Table 1, cases had significantly lower average levels of respiratory support
225 requirement and significantly higher D-Dimer values than controls.

226 Comparing maximum respiratory support requirement in cases versus controls, we noted that
227 32/50 (64.0%) of the controls required intensive modes of respiratory support (NRBM,
228 HFNC, NIV, Intubation) as compared to 10/43 (23.26%) of the cases. This difference was
229 statistically significant ($X^2 = 2.022$, df 6, $p = 0.001$).

230 Mortality was 51.2% in the case group compared with 26.0% in the control group, being
231 significantly higher in cases compared to controls ($X^2 = 6.237$, df 1, $p = 0.018$; OR 2.98,
232 95CI_{OR} 1.25–7.11).

233 Table 2 shows that patients requiring higher modalities of oxygen support (NRBM, HFNC,
234 NIV, invasive ventilation) had higher mortality in both cases and controls. We observed that
235 in both low flow oxygen and high flow oxygen subgroups, cases had significantly higher
236 mortality than controls. However, the difference in mortality between cases and controls was
237 striking in the low flow subgroup. In the latter, despite maintaining satisfactory oxygen
238 saturation on room air or with minimal oxygen support, the mortality was 7.5 times higher in

239 COVID stroke patients as compared to controls (Low flow: 42.4% vs 5.6%, $X^2= 7.626$, df 1,
240 $p = 0.006$; OR 12.53, 95CI_{OR} 1.49–105.58; High flow: 80.0% vs 37.5%, $X^2= 5.517$, df 1, $p =$
241 0.030; OR 6.67, 95CI_{OR} 1.21–36.74).

242 Accurate dates of admission and discharge/death were available for 26 of 43 cases, and all 50
243 controls. Mean duration of hospitalization for cases was 13.25 days for those who survived
244 and 9.36 days for those who died. For controls it was 12.57 days for those who survived and
245 11.54 days for those who died.

246 Table 3 shows the results of binary logistic regression analysis to determine predictors of
247 mortality in the case group and control group. The level of respiratory support requirement
248 was the sole independent predictor of mortality among the cases. In controls, mortality was
249 predicted by increasing age and female sex in addition to respiratory support requirement.

250 **Discussion**

251 During the COVID-19 pandemic, it was recognized early on that the presence of thrombosis
252 in multiple organ systems points to thromboembolism being an integral component in the
253 pathogenesis of this novel disease.(10,11,14,15)

254 During the months of May and June 2020, we noted many patients presenting with
255 thromboembolic phenomena as an early manifestation of COVID-19, or developing these
256 complications during admission. Hence, the first part of our study comprised documentation
257 of acute cerebral and cardiac thromboembolic events during admission for COVID-19
258 infection. Acute neurovascular and cardiac events associated with COVID-19 at our centre
259 included 68 cases of stroke and 122 cases of ACS during the period of April-November 2020.
260 Of these 68 strokes, 49 had ischemic strokes. Of these 49 COVID-19 associated ischemic
261 strokes, 22 (51.2%) presented with only stroke and no respiratory signs and symptoms of
262 COVID-19 (data in press). This possible early thromboembolic effect of COVID-19 on the

263 neurovascular system, prompted us to investigate and study patients with ischemic stroke as a
264 primary presentation of COVID-19, in the second part of our study. The occurrence of
265 thromboembolic phenomenon early in the course of COVID-19 disease has also been
266 observed in other studies by Pillai et al.(14) Stefanini et al(16) and Mao et al.(17)

267 43 patients satisfied our inclusion criteria for this study viz., ischemic stroke within 72 hours
268 of onset of first symptoms of COVID-19. As complete data was available for the patients
269 with stroke, we compared characteristics of stroke patients with corresponding findings in
270 patients without thromboembolic manifestations of the disease. A detailed similar analysis of
271 the patients with ACS was not possible, due to lack of complete data.

272 Figure 1 shows the timeline of admission of all COVID-19 cases, COVID-19 cases with ACS
273 and COVID-19 cases with stroke, under medicine and cardiology departments, at our centre.
274 Whereas the peak of cardiac cases was in May and June 2020, the peak of stroke cases was in
275 September and October 2020, at which time stroke and ACS incidence were approximately
276 the same. As both ACS and stroke are thrombo-inflammatory manifestations of the virus, it is
277 surprising that these two events have shown different peaks (Figure 1). ACS incidence
278 showed a gradual decline after June whereas stroke incidence gradually rose to peak in
279 September-October. In September and October 2020, the number of COVID-19 admissions
280 (only patients with higher category oxygen requirement, beyond nasal cannula at 4
281 litres/minute, or those with systemic complications, are admitted at our centre) had fallen
282 steeply, with ACS cases also showing a gradual decline. It is possible that patients with
283 severe strokes may have expired at home due to difficulties of travel in a severely disabled
284 state during the lockdown in peak months. Hence, the rise in stroke admissions later may
285 have been due to better facilities of transportation, as the lockdown eased in the city in the
286 later months.

287 Among the 43 stroke cases, CT confirmation of infarct and arterial territory could be made in
288 37 patients. Four patients were diagnosed clinically as carotid territory stroke, and the lack of
289 hemorrhage on the CT classified them as possible early infarcts. Due to the difficulties
290 inherent in and peculiar to the COVID-19 situation in a large public hospital, a repeat
291 imaging study could not be done in these patients. However, it was clear that in those with
292 imaging confirmation, the infarcts were either large or multiple, or in eloquent areas; 18.9%
293 being in both anterior and posterior circulation territories, 10.8% in vertebrobasilar territory,
294 and even among the carotid territory strokes, almost half being large hemispherical strokes.
295 Additionally, 67.8% of those who had a CT angiography done, showed evidence of LVO,
296 portending the possibility of enlargement of infarct area.

297 CRP levels, while being over 10 times the upper limit of normal level in both groups, showed
298 no significant difference between the two groups (Table 1). This was not surprising as both
299 the groups fell into the moderate to severe infection categories, in terms of respiratory and
300 other systemic involvement. While both cases and controls had high levels of D-Dimer (more
301 than thrice the upper limit of normal value), the case group had a significantly higher D-
302 Dimer level as compared to the control group. A deranged coagulation function, including
303 elevated D-Dimer, has been demonstrated to lead to disease progression of COVID-
304 19.(18,19) Several studies have reported elevated levels of CRPs and D-Dimer in patients
305 with COVID-19.(3,4,17,20,21) Additionally, COVID-19 associated inflammation resulting in
306 a hypercoagulable state has been well documented.(21,22)

307 Our study showed that the control group required a higher level of respiratory support care
308 than the case group, the number of patients requiring NRBM, HFNC or intubation being 32
309 (64%) in control group, as compared to 10 (23.26%) in case group. This could be related to
310 two factors: the higher survival rate in the control group (mortality in case and control groups
311 being 51.2% and 26.0% respectively), and longer mean duration of survival in the control

312 group (the patients in the case group who died in hospital, survived for an average of 9.3 days
313 as compared to 11.5 days in the patients who expired in the control group).

314 In the overall 'low flow oxygen support group,' the 7 times higher death rate in the case
315 group as compared to the control group, was striking. Death in the case group probably
316 occurred before progression to higher levels of respiratory support, due to severe central
317 nervous system insult, without having severe respiratory involvement. The phenomenon of
318 increased risk of thrombus formation leading to stroke (postulated to be due to viral
319 involvement of the endothelium), in the absence of severe respiratory disease, has been
320 previously documented.(15) Contrarily, other authors have posited that the incidence of
321 stroke in COVID-19 may be related to severity of infection.(17,21)

322 In this study, although higher modes of respiratory support were less frequent in the case
323 group, respiratory distress level requiring higher modality of support predicted mortality
324 within the group. The respiratory distress could have been due to COVID-19 lung infection
325 or due to aspiration pneumonia resulting from obtunded sensorium in stroke.

326 The prediction of mortality by increasing age, as seen in the control group in our study, has
327 been well documented by various authors.(23,24) However, most studies have shown that
328 men have a higher risk of COVID-19 related death than women,(23,25) contrary to our
329 findings in the control group. Our sample size for the control group was small, and this
330 limitation could have led to this finding.

331 A major limitation of our study is the lack of documentation of clinical and subclinical
332 pulmonary thromboembolic phenomena in the case and control groups. This was highly
333 probable, given the thrombo-inflammatory milieu, and the concomitantly existing cerebral
334 thrombosis. It is possible that this was more common in the case group and could have
335 contributed to the mortality. We did not take pulmonary thromboembolism into account in

336 our analysis, as complete data on CT pulmonary angiography was not available in many
337 patients.

338 In conclusion, our comparison of a thromboembolic cerebral presentation of COVID-19 with
339 a clinically non-thromboembolic presentation of COVID-19, demonstrated higher D-Dimer
340 levels, and a higher mortality in the absence of prominent respiratory compromise, in the
341 former group. The higher mortality was possibly due to the severity of stroke and presence of
342 proximal LVOs. We could not compare mortality in COVID-19 associated strokes with a
343 cohort of non-COVID associated strokes in the same period, as our regular admissions were
344 severely limited during the pandemic. A meta-analysis of stroke in COVID-19 has
345 highlighted that the mean mortality rate among stroke patients with COVID-19 infection was
346 46.7% compared to only 8.7% among those without COVID-19 infection.(26)

347 **References**

- 348 1. Morassi M, Bagatto D, Cobelli M, D'Agostini S, Gigli GL, Bnà C, et al. Stroke in
349 patients with SARS-CoV-2 infection: case series. *J Neurol*. 2020 Aug;267(8):2185–92.
- 350 2. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and
351 Stroke in a New York Healthcare System. *Stroke*. 2020;51(7):2002–11.
- 352 3. TunÇ A, ÜnlÜbaŞ Y, Alemdar M, AkyÜz E. Coexistence of COVID-19 and acute
353 ischemic stroke report of four cases. *J Clin Neurosci*. 2020 Jul;77:227–9.
- 354 4. Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al.
355 Characteristics of ischaemic stroke associated with COVID-19. *J Neurol Neurosurg*
356 *Psychiatry*. 2020 Aug;91(8):889–91.


- 357 5. Kihira S, Schefflein J, Chung M, Mahmoudi K, Rigney B, Delman BN, et al. Incidental
358 COVID-19 related lung apical findings on stroke CTA during the COVID-19 pandemic.
359 J Neurointerv Surg. 2020 Jul;12(7):669–72.
- 360 6. Dakay K, Cooper J, Bloomfield J, Overby P, Mayer SA, Nuoman R, et al. Cerebral
361 Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The
362 Literature. J Stroke Cerebrovasc Dis. 2021 Jan;30(1):105434.
- 363 7. Lodigiani C, Iapichino G, Carezzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous
364 and arterial thromboembolic complications in COVID-19 patients admitted to an
365 academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
- 366 8. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al.
367 Confirmation of the high cumulative incidence of thrombotic complications in critically
368 ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020 Jul;191:148–
369 50.
- 370 9. Poyiadji N, Cormier P, Patel PY, Hadied MO, Bhargava P, Khanna K, et al. Acute
371 Pulmonary Embolism and COVID-19. Radiology. 2020 Dec;297(3):E335–8.
- 372 10. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al.
373 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter
374 prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.
- 375 11. Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-
376 19) through the prism of Virchow’s triad. Clin Rheumatol. 2020 Sep;39(9):2529–43.

- 377 12. Maier CL, Truong AD, Auld SC, Polly DM, Tanksley C-L, Duncan A. COVID-19-
378 associated hyperviscosity: a link between inflammation and thrombophilia? *Lancet*.
379 2020 Jun 6;395(10239):1758–9.
- 380 13. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with
381 endothelial activation. *Thromb Res*. 2020 Jun;190:62.
- 382 14. Pillai P, Joseph JP, Fadzillah NHM, Mahmud M. COVID-19 and Major Organ
383 Thromboembolism: Manifestations in Neurovascular and Cardiovascular Systems. *J*
384 *Stroke Cerebrovasc Dis*. 2021 Jan;30(1):105427.
- 385 15. Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS. Macrothrombosis and
386 stroke in patients with mild Covid-19 infection. *J Thromb Haemost*. 2020
387 Aug;18(8):2031–3.
- 388 16. Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, et al.
389 ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and
390 Angiographic Outcomes. *Circulation*. 2020 Jun 23;141(25):2113–6.
- 391 17. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of
392 Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*.
393 2020 01;77(6):683–90.
- 394 18. Han H, Yang L, Liu R, Liu F, Wu K-L, Li J, et al. Prominent changes in blood
395 coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med*. 2020 Jun
396 25;58(7):1116–20.

- 397 19. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with
398 poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020
399 Apr;18(4):844–7.
- 400 20. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein,
401 procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.
402 *Ther Adv Respir Dis.* 2020;14:1753466620937175–1753466620937175.
- 403 21. Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease
404 following COVID-19: a single center, retrospective, observational study. *Stroke Vasc*
405 *Neurol.* 2020 Sep;5(3):279–84.
- 406 22. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19.
407 *J Thromb Haemost.* 2020 Jul;18(7):1559–61.
- 408 23. Yanez ND, Weiss NS, Romand J-A, Treggiari MM. COVID-19 mortality risk for older
409 men and women. *BMC Public Health.* 2020 Nov 19;20(1):1742.
- 410 24. Kang SJ, Jung SI. Age-Related Morbidity and Mortality among Patients with COVID-
411 19. *Infect Chemother.* 2020 Jun;52(2):154–64.
- 412 25. Bhopal SS, Bhopal R. Sex differential in COVID-19 mortality varies markedly by age.
413 *Lancet.* 2020 Aug 22;396(10250):532–3.
- 414 26. Lee KW, Yusof Khan AHK, Ching SM, Chia PK, Loh WC, Abdul Rashid AM, et al.
415 Stroke and Novel Coronavirus Infection in Humans: A Systematic Review and Meta-
416 Analysis. *Front Neurol.* 2020;11:579070.
- 417
- 418

419 **Figures**

420 Figure 1. Time trend of COVID-19cases, strokes, and acute coronary syndromes



421

422 ACS: Acute Coronary Syndrome

423

424

425

426

427

428

429

430

431

432

433

434 **Tables**

435 Table 1. Comparison of means for selected variables in the case and control groups.

Variables		N	Mean	Mean Difference	95% Confidence Interval of the Difference		P value
					Lower	Upper	
Age	Case	43	51.51	-0.11	-6.29	6.08	0.972
	Control	50	51.62				
No. of Comorbidities	Case	43	1.00	0.20	-0.15	0.55	0.255
	Control	50	.80				
SpO ₂ on Admission	Case	43	89.12	2.70	-3.05	8.45	0.354
	Control	50	86.42				
Respiratory Distress Level	Case	43	1.14	-1.58	-2.27	-0.89	0.000
	Control	50	2.72				
Platelet count/ μ L	Case	39	214925.64	3160.42	-55915.90	62236.75	0.914
	Control	23	211765.22				
S. Creatinine mg/dL	Case	41	1.24	-0.01	-0.31	0.29	0.936

	Control	50	1.26				
S. Creatinine µmol/L	Case	41	109.99	-1.07	-27.69	25.55	0.936
	Control	50	111.06				
CRP mg/L	Case	20	59.63	-20.73	-53.77	12.30	0.212
	Control	50	80.36				
D-dimer ng/mL	Case	20	2975.44	1472.02	110.72	2833.32	0.035
	Control	50	1503.42				
D-dimer nmol/L	Case	20	32.59	16.12	1.21	31.03	0.035
	Control	50	16.47				

436 SpO2: percentage saturation of oxygen

437 CRP: C-Reactive protein

438

439

440

441

442

443

444

445 Table 2. Maximum respiratory support requirement versus mortality in case and control

446 groups

	Case				Control			
	Died		Survived		Died		Survived	
	Count	%	Count	%	Count	%	Count	%
Room air	5	25.0	15	75.0	0	0.0	8	100.0
Nasal cannula	7	70.0	3	30.0	1	10.0	9	90.0
Venturi	2	66.7	1	33.3	0	0.0	0	0.0
NRBM	6	75.0	2	25.0	2	10.5	17	89.5
HFNC	1	100.0	0	0.0	2	50.0	2	50.0
NIV	1	100.0	0	0.0	0	0.0	1	100.0
Intubation	0	0.0	0	0.0	8	100.0	0	0.0
Low flow group	14	42.4	19	57.6	1	5.6	17	94.4
High flow group	8	80.0	2	20.0	12	37.5	20	62.5

447 Low flow: Room air, Nasal canula and Venturi modes

448 High flow: NRBM, HFNC, NIV and Intubation modes

449

450

451

452

453

454 Table 3. Regression analysis for predictors of mortality in cases and controls

CASE/CONTROL		B	Exp(B)	95% C.I. for EXP(B)		Sig.
				Lower	Upper	
Case	Age	-.038	.963	.907	1.022	.211
	Sex(F)	.896	2.450	.472	12.731	.287
	No. of comorbidities	.558	1.747	.663	4.605	.259
	Respiratory support requirement	1.070	2.915	1.383	6.143	.005
	Constant	.065	1.067			.958
Control	Age	.240	1.271	1.030	1.569	.026
	Sex(F)	5.823	337.932	1.984	57559.548	.026
	No. of comorbidities	-2.406	.090	.007	1.235	.072
	Respiratory support requirement	2.700	14.877	1.917	115.460	.010
	Constant	-23.396	.000			.012

455

456

457

458